SNF Platform Study of HR+/ HER2-advanced Breast Cancer

The purpose of this study is to establish a prospective, multi-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had previously used CDK4/6 inhibitors.

Trial Details

NCT ID

NCT05594095

Phase

PHASE2

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

PIK3CA inhibitor
AKT inhibitor
Carrelizumab
Famitinib
Fluzoparib
Dalpiciclib

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Female aged ≥18 years;
HR+/HER2- invasive breast cancer confirmed by histology (specific definition: ER \>10% positive tumor cells by immunohistochemistry is defined as E…
Locally advanced breast cancer (unable to undergo radical local treatment) or recurrent metastatic breast cancer;
HR+/HER2- advanced breast cancer patients who had previously received CDK4/6 inhibitor therapy;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →